Exicure, Inc. (XCUR)
Price:
5.32 USD
( + 1.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
NEWS
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
globenewswire.com
2025-10-06 07:00:00Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise REDWOOD CITY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today shared recent progress for its lead program, burixafor (GPC-100), outlined upcoming strategic priorities, and introduced new members of its leadership team who will help drive the company's next phase of growth.
Exicure Posts Wider Loss in Fiscal Q2
fool.com
2025-08-08 16:19:26Exicure Posts Wider Loss in Fiscal Q2
Exicure, Inc. Reports Second Quarter 2025 Financial Results
businesswire.com
2025-08-08 16:01:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results.
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
businesswire.com
2025-08-04 16:37:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements.
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
businesswire.com
2025-08-01 16:01:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients.
Exicure, Inc. Reports First Quarter 2025 Financial Results
businesswire.com
2025-06-27 16:01:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Q1 2025 earnings release.
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
businesswire.com
2025-05-28 16:58:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q.
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
businesswire.com
2025-05-05 08:00:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant.
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
businesswire.com
2025-04-14 18:11:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma.
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
businesswire.com
2025-04-11 19:42:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML).
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
businesswire.com
2025-03-13 16:08:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Issuance of New Patent in Australia.
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
businesswire.com
2025-01-23 00:17:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
businesswire.com
2025-01-22 16:01:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
businesswire.com
2024-12-26 20:08:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Partners with GPCR Therapeutics Inc. to Fuel New Growth in Biotech.
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
businesswire.com
2024-12-21 13:48:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
businesswire.com
2024-12-20 16:42:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.
No data to display
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
globenewswire.com
2025-10-06 07:00:00Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise REDWOOD CITY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today shared recent progress for its lead program, burixafor (GPC-100), outlined upcoming strategic priorities, and introduced new members of its leadership team who will help drive the company's next phase of growth.
Exicure Posts Wider Loss in Fiscal Q2
fool.com
2025-08-08 16:19:26Exicure Posts Wider Loss in Fiscal Q2
Exicure, Inc. Reports Second Quarter 2025 Financial Results
businesswire.com
2025-08-08 16:01:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results.
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
businesswire.com
2025-08-04 16:37:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements.
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
businesswire.com
2025-08-01 16:01:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients.
Exicure, Inc. Reports First Quarter 2025 Financial Results
businesswire.com
2025-06-27 16:01:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Q1 2025 earnings release.
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
businesswire.com
2025-05-28 16:58:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q.
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
businesswire.com
2025-05-05 08:00:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant.
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
businesswire.com
2025-04-14 18:11:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma.
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
businesswire.com
2025-04-11 19:42:00REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML).
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
businesswire.com
2025-03-13 16:08:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Issuance of New Patent in Australia.
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
businesswire.com
2025-01-23 00:17:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
businesswire.com
2025-01-22 16:01:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
businesswire.com
2024-12-26 20:08:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Partners with GPCR Therapeutics Inc. to Fuel New Growth in Biotech.
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
businesswire.com
2024-12-21 13:48:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
businesswire.com
2024-12-20 16:42:00CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.